X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE IPCA LABS SUVEN LIFE/
IPCA LABS
 
P/E (TTM) x 19.0 28.1 67.7% View Chart
P/BV x 4.2 3.3 124.8% View Chart
Dividend Yield % 0.5 0.1 389.9%  

Financials

 SUVEN LIFE   IPCA LABS
EQUITY SHARE DATA
    SUVEN LIFE
Mar-18
IPCA LABS
Mar-18
SUVEN LIFE/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs251695 36.1%   
Low Rs155400 38.8%   
Sales per share (Unadj.) Rs49.1260.2 18.9%  
Earnings per share (Unadj.) Rs9.719.0 51.2%  
Cash flow per share (Unadj.) Rs11.433.1 34.5%  
Dividends per share (Unadj.) Rs1.501.00 150.0%  
Dividend yield (eoy) %0.70.2 404.9%  
Book value per share (Unadj.) Rs60.3213.0 28.3%  
Shares outstanding (eoy) m127.28126.20 100.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.12.1 196.2%   
Avg P/E ratio x20.928.9 72.3%  
P/CF ratio (eoy) x17.816.6 107.5%  
Price / Book Value ratio x3.42.6 130.9%  
Dividend payout %15.45.3 292.8%   
Avg Mkt Cap Rs m25,82569,120 37.4%   
No. of employees `0001.113.3 8.1%   
Total wages/salary Rs m6137,359 8.3%   
Avg. sales/employee Rs Th5,832.62,477.4 235.4%   
Avg. wages/employee Rs Th571.5555.2 102.9%   
Avg. net profit/employee Rs Th1,153.8180.6 638.7%   
INCOME DATA
Net Sales Rs m6,25332,836 19.0%  
Other income Rs m233418 55.7%   
Total revenues Rs m6,48533,254 19.5%   
Gross profit Rs m1,9824,505 44.0%  
Depreciation Rs m2131,777 12.0%   
Interest Rs m46240 19.3%   
Profit before tax Rs m1,9552,905 67.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m718511 140.5%   
Profit after tax Rs m1,2372,394 51.7%  
Gross profit margin %31.713.7 231.0%  
Effective tax rate %36.717.6 208.8%   
Net profit margin %19.87.3 271.3%  
BALANCE SHEET DATA
Current assets Rs m5,62219,455 28.9%   
Current liabilities Rs m1,16810,076 11.6%   
Net working cap to sales %71.228.6 249.4%  
Current ratio x4.81.9 249.4%  
Inventory Days Days8198 83.2%  
Debtors Days Days3667 53.7%  
Net fixed assets Rs m3,32520,260 16.4%   
Share capital Rs m127252 50.4%   
"Free" reserves Rs m7,54726,633 28.3%   
Net worth Rs m7,67426,886 28.5%   
Long term debt Rs m142,340 0.6%   
Total assets Rs m9,13541,173 22.2%  
Interest coverage x43.213.1 330.1%   
Debt to equity ratio x00.1 2.1%  
Sales to assets ratio x0.70.8 85.8%   
Return on assets %14.06.4 219.5%  
Return on equity %16.18.9 181.0%  
Return on capital %26.010.8 241.9%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m5,06615,642 32.4%   
Fx outflow Rs m2,0014,884 41.0%   
Net fx Rs m3,06510,759 28.5%   
CASH FLOW
From Operations Rs m6993,411 20.5%  
From Investments Rs m-6-1,354 0.5%  
From Financial Activity Rs m-577-1,304 44.2%  
Net Cashflow Rs m116753 15.4%  

Share Holding

Indian Promoters % 63.4 45.9 138.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.4 -  
FIIs % 0.0 25.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.4 209.8%  
Shareholders   37,287 36,892 101.1%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare SUVEN LIFE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Sep 21, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUVEN LIFE WITH

MARKET STATS